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Background: The extent to which MS patients with cognitive dysfunction can accurately self-report outcomes has
been a crucial issue. The aim of this study was to quantify and compare the relevance of the quality of life (QoL)
assessment between two populations with a high occurrence of cognitive dysfunction, specifically in individuals
with multiple sclerosis (MS) and in individuals suffering from schizophrenia (SCZ).
Methods: Design: A cross-sectional study was performed using the following inclusion criteria: MS and SCZ patients
were diagnosed according to the McDonald criteria and DSM-IV criteria, respectively. Data on sociodemographic
(age, gender, education level) and clinical (disease severity, disease duration) factors, QoL (disease-specific
questionnaires, MusiQoL and SQoL) and cognitive performance (executive, memory, and attention functions) were
collected. Non-impaired and impaired populations were defined according to the French norms. Psychometric
properties were compared to those reported in reference populations, which were assessed in the respective
validation studies. Suitability indices were provided used to quantitatively compare how the structures in the
different populations matched with the initial structure of the questionnaires (reference populations).
Results: One hundred and twenty-four MS patients and 113 SCZ patients were enrolled. Factor analysis was
performed on the impaired populations and revealed that the questionnaire structure adequately matched the
initial structure of the disease-specific QoL questionnaires. All of the suitability indices of construct and external
validity in the non-impaired populations ranged from 70 to 100%.
Conclusions: Our study suggested that cognitive dysfunction did not compromise the reliability or validity of the
self-reported QoL questionnaires among subjects with cognitive dysfunction, such as MS and SCZ. Thus, this report
may clarify the relevance of using self-reported QoL assessments in clinical practice.
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The assessment of quality of life (QoL) has been consid-
ered increasingly important with regard to the evaluation
of disease progression, treatment and the management of
care provided to patients with chronic illness. The US
Food and Drug Administration and the European Medi-
cines Agency have provided detailed recommendations for
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article, unless otherwise stated.to consider QoL issues, QoL assessment remains under-
utilized in clinical practice [3,4].
QoL is commonly assessed using self-reported question-
naires. The extent to which patients with cognitive dys-
function can accurately self-report their QoL has been a
crucial issue that has only been partially examined [5].
Few studies have investigated this issue in specific popula-
tions, such as in patients with multiple sclerosis (MS)
[6,7], patients with serious chronic mental illnesses [8,9],
in elderly populations [10,11], and in patients with trau-
matic brain injury [12]. These studies have produced con-
flicting results, where some studies have demonstratedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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[6,7,9] to produce valid and reliable QoL measures. How-
ever, these studies provided restricted data regarding valid-
ity and reliability and did not report whether the structure
of the questionnaire described in the impaired populations
was well adapted when the QoL measure was used
in these individuals. More recent studies have reported
strong arguments in support of the conclusion that cog-
nitively impaired patients can reliably and consistently
respond to disease-specific questionnaires, where such
studies used an interesting approach based on quantifica-
tion of the relevance of the QoL assessment [15-17]. This
quantification relied on suitability indices based on deci-
sion rules. These rules defined expected psychometric
properties according to the appropriate standards [18,19]
and the properties reported in the reference population in
the initial validation publication of the QoL questionnaire.
This approach enables the determination of the relevance
of QoL measures in different populations independent of
the questionnaire used.
In this study, we compared the relevance of the QoL as-
sessment between 2 populations of subjects with cognitive
dysfunction to determine if the nature of the disease influ-
enced the individual’s ability to accurately report his or
her life experience. Cognitive deficits occur in a large pro-
portion of patients with MS [20,21] as well as in patients
suffering from schizophrenia (SCZ) [22,23]. In these 2
populations, similar neuroimaging abnormalities were re-
ported [24,25] and all cognitive domains, such as executive
functions, memory, and attention/concentration are af-
fected. The aim of this study was to explore the validity of
disease-specific QoL questionnaires in patients with im-
paired cognitive function and to compare these findings
between MS and SCZ patients.
Methods
Study design and participants
This study utilized a cross-sectional design. The inclusion
criteria for MS patients included the following: an MS
diagnosis according to the McDonald criteria [26], any
subtype of MS, no neurological disease (other than MS),
and no history of severe mental illness (except depression
disorders). The inclusion criteria for SCZ patients in-
cluded the following: age, diagnosis of SCZ according to
the Diagnostic and Statistical Manual of Mental Disorders,
4th ed. (DSM-IV) criteria [27], and no neurological dis-
ease. All of the patients were over 18 years old, out-
patients, in a stable disease phase (no relapse during the
last 3 months), and native French speakers. MS patients
were recruited from the neurology department of a public
French academic teaching hospital (Marseille, France) and
SCZ patients were recruited from two psychiatric hospitals
(Marseille and Toulon, France). The French Ethics
Committee approved this study (Comité Consultatif deProtection des Personnes dans la Recherche Biomédi-
cale, Marseille, France). Informed consent was obtained
from all subjects.
Data collection
The collected data included sociodemographic informa-
tion, clinical characteristics, QoL and cognitive assess-
ments. The sociodemographic (age, gender, and education
level) and clinical (disease duration) data were recorded
for each patient. Disease severity was assessed using the
Expanded Disability Status Scale (EDSS) [28] and the Posi-
tive and Negative Syndrome Scale (PANSS) for MS and
SCZ patients [29], respectively.
QoL was assessed using the French versions of disease-
specific questionnaires: the MusiQoL for MS patients and
SQoL for SCZ patients. The MusiQoL is a well-validated
MS-specific questionnaire [30] consisting of 31 items that
describes nine dimensions and provides a global index
score: activity of daily living (ADL), psychological well-
being (PWB), symptoms (SPT), relationships with friends
(RFr), relationships with family (RFa), relationships with
the health care system (RHCS), sentimental and sexual life
(SSL), coping (COP), and rejection (REJ). The SQoL is a
self-administered QoL questionnaire designed for people
with schizophrenia [31,32]. It consists of 18 items that
describes 8 dimensions (psychological well-being (PsW),
self-esteem (SE), family relationships (RFa), relationships
with friends (RFr), resilience (RE), physical well-being
(PhW), autonomy (AU) and sentimental life (SL)) and pro-
vides a total score (index). For the two questionnaires, the
dimension and index scores range from 0, which indicates
the lowest QoL, to 100, which indicates the highest QoL.
Cognition assessment
For both patient groups, cognitive assessment included
executive function, memory, and attention performances.
The executive function performance was assessed using
both the French versions of the Stroop color-word test
[33] and the Trail Making test (TMT) [34]. Memory per-
formance was assessed using the long-short-delay tests of
the French version of Grober and Buschke [35] in MS pa-
tients, and the long-short-delay subscales of the French
version of the Wechsler Memory Scale [36] in SCZ pa-
tients. Attention performance was evaluated using the at-
tention/concentration subscale of the French version of
the Wechsler Memory Scale [36]. The same trained psych-
ologist administered the tests in a standardized manner
and the same instructions were given to the subjects prior
to each test. Applying French normative values according
to age, gender, and educational level (except for the
Wechsler Memory Scale), the patients were divided into
the following categories of cognitive function: 1) executive
function: non-impaired (normal Stroop test and normal
TMT) and impaired (other cases) [37]; 2) memory
Baumstarck et al. BMC Neurology 2014, 14:78 Page 3 of 11
http://www.biomedcentral.com/1471-2377/14/78function: non-impaired (normal short-delay memory and
normal long-delay memory) and impaired (other cases)
[35,36]; 3) attention function: non-impaired (normal atten-
tion/concentration subscale) and impaired (other cases)
[36]. These categorizations enabled the characterization of
each patient as a no or low-impaired (no impairment or
one impaired function) and highly-impaired global func-
tion (2 or 3 impaired functions).
Statistical analysis
Statistical analyses were performed on the 4 populations
defined above, i.e., no/low-impaired and highly-impaired
groups for the 2 diseases, using the same procedure re-
ported in the initial validation publications (reference pop-
ulations) for MusiQoL [30] and SQoL [32]. For each
group, the psychometric properties were compared to
those reported in the reference population as assessed in
the validation study of each questionnaire [30,32]. The
structures of the MusiQoL/SQoL were examined in the
no/low-impaired and highly-impaired populations using
factor analysis to determine how these structures matched
with the initial structure of the questionnaire using princi-
pal component factor analyses with a varimax rotation
[18,19]. For each population, the proportion of factors
identified from the initial factor structure of the Musi-
QoL/SQoL and the proportion of items projected to their
initial dimension were obtained.
The multidimensional structure (construct validity) was
verified using the multi-trait/multi-item analysis program
[38]. The internal structural validity was assessed by inves-
tigating item-dimension correlations. The item internal
consistency (IIC) was calculated by correlating each item
with its scale, and the item discriminant validity (IDV)
was assessed by determining the extent to which the items
correlated with the dimension that they were hypothesized
to represent compared to the correlations with other di-
mensions. Floor and ceiling effects were determined to
assess the homogeneous repartition of the response
distribution. For each dimension, the internal consistency
reliability was evaluated using Cronbach’s alpha coeffi-
cient [39].
The unidimensionality of each dimension was ex-
plored by computing the item goodness-of-fit statistics
(INFIT), which was obtained from Rasch analyses [40].
The INFIT values ranged from 0.7 to 1.2 to ensure that
all of the scale items measured the same concept.
To explore external validity, Spearman’s correlation
coefficients were used to investigate the relationships
between the MusiQoL and SF36 dimensions in each
group, and the associations between the MusiQoL dimen-
sion scores and sociodemographic and clinical features
were reported similar to the validation study. For qualita-
tive variables, the mean dimension scores of the MusiQoL
were compared across patient groups (e.g., gender,educational level, marital status, and occupational status)
using one-way analysis of variance. Quantitative variables
(e.g., age, EDSS score, and MS duration) were analyzed
using Spearman’s correlation coefficients. Acceptability
was assessed by calculating the percentage of missing data
per dimension. Data analyses were performed using SPSS
11.0, MAP-R, LISREL and WINSTEP software.
To quantify the manner in which each of the 4 struc-
tures matched with the initial structure (2 reference struc-
tures), suitability indices were calculated as previously
described [15]. Decision rules, which were established by
experts in QoL, were used to define satisfactory properties
according to appropriate standards [18,19]. The means of
the different proportions were calculated to produce a
suitability index of the ‘construct validity’ and a suitability
index of the ‘external validity’.
Results
One hundred and twenty-four consecutive MS patients
and 113 patients with schizophrenia were enrolled in
this study. The sociodemographic and clinical features
are listed in Table 1. At the timepoint of performing
QoL assessment, 118 (95%) MS patients were taking
disease-modifying drugs and 109 (96%) patients with
schizophrenia were taking atypical antipsychotics (aver-
age dose of chlorpromazine of approximately 570 mg).
According to the French normative values and to the
definition of global cognitive status, 50 MS patients were
categorized as cognitively no/low-impaired and 49 pa-
tients were categorized as cognitively highly-impaired. In
addition, 40 SCZ patients were categorized as cognitively
no/low-impaired and 67 patients were categorized as
cognitively highly-impaired.
Construct validity
In the MS sample population, seven of the 9 initial fac-
tors were identified in the no/low-impaired group (REJ
and SSL dimensions were not clearly identified), and 8
initial factors were found in the highly-impaired group
(COP dimension was not detected). Twenty-seven and
29 of the 31 items contributed to the initial dimension
in the no/low-impaired and highly-impaired groups,
respectively.
The proportion of dimensions with IIC, which was
greater than 0.2 compared to the reference population,
was higher in the highly-impaired population compared
to the no/low-impaired population. The proportion of
dimensions with IDV, which was not greater than 0.2
compared to the reference population, was moderately
satisfactory in both populations. The correlation for each
item with its contributive dimension (IIC) was higher
compared to the other dimensions (IDV) for 6 and 7 di-
mensions in the no/low- and highly-impaired popula-
tions, respectively. Cronbach’s alpha coefficients were
Table 1 Sample characteristics
MS SCZ
Sociodemographic characteristics N = 124 N = 113
Sex ratio (men:women) 53:71 Sex ratio 79:34
Age in years: M ± SD 45.05 ± 10.80 Age 38.60 ± 10.80
Educational level <12 years 65 (52.8%) <12 years 62 (54.9%)
≥ 12 years 58 (47.2%) ≥ 12 years 51 (45.1%)
Clinical characteristics
Disease subtypes Relapsing remitting 36 (29.0%) Paranoid schizophrenia 60 (53.1%)
Primary progressive 20 (16.3%)
Secondary progressive 61 (49.6%)
Clinically isolated syndrome 7 (5.7%)
Disease duration in years: median [range] 10 [0–31] 22 [19-27]
Severity: median [range] EDSS 4.75 [1-8] PANSS 61 [51–75]
MD ± SD mean ± standard deviation.
MS multiple sclerosis, SCZ schizophrenia.
EDSS Expanded Disability Status Scale.
PANSS Positive and Negative Syndrome Scale.
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impaired group. In addition, both populations showed
satisfactory INFIT statistics. The floor effects were less
than 10% compared to the reference population for 8
and 4 dimensions in the no/low-impaired and highly-
impaired groups, respectively. The proportion of dimen-
sions with a ceiling effect exceeding 10% compared to
the reference population was higher in the highly-
impaired population compared to the no/low-impaired
population. The suitability indices of the construct valid-
ity were 82% and 78% in the highly-impaired and no/
low-impaired populations, respectively.
In the SCZ sample, the 8-factor structure of the SQoL
was clearly detected in the no/low and highly-impaired
groups. Sixteen of the 18 items contributed to the initial
dimension in the no/low-impaired and highly-impaired
groups, respectively. The proportion of dimensions with
IIC that was greater than 0.2 from the reference popula-
tion was unsatisfactory in both populations. Moreover, the
correlation for each item with its contributive dimension
(IIC) was higher compared to the others (IDV) for 5 di-
mensions in the no/low- and highly-impaired populations.
Cronbach’s alpha coefficients were satisfactory for 6 of the
8 dimensions in the no/low-impaired group. Furthermore,
the INFIT statistics were satisfactory for both populations.
The floor effects were less than 10% compared to the ref-
erence population for 6 dimensions in both groups, and
the ceiling effects were less than 10% from the reference
population for 4 and 5 dimensions in the no/low- and
highly-impaired populations, respectively.
The suitability indices of the construct validity were
80% in the highly-impaired population and 74% in the
no/low-impaired population (Figure 1). Further details
are provided in Table 2 and Table 3.External validity
In MS individuals, women generally reported lower scores
compared to men excepted in the sentimental and sexual
life independent of cognitive status. The suitability index
was more satisfactory in the highly-impaired population
compared to the no- or low-impaired population. The pro-
portion of dimensions with an effect size of less than 0.2
compared to the reference population for educational level
was moderately satisfactory in both populations. In SCZ
individuals, the proportion of dimensions with an effect
size of less than 0.2 compared to the reference population
for gender and occupational status was more satisfactory
in both the no/low and highly-impaired groups.
As expected, age and disease duration almost never
correlated with the QoL dimensions in the MS and SCZ
populations. Findings related to relationships with dis-
ease severity and QoL scores were close compared to
those of the 2 reference populations.
Taken together, the suitability indices of external valid-
ity in the no/low- and highly-impaired populations were
80% and 87% for the MS population and 85% and 88%
for the SCZ population, respectively (Figure 2). These
results are summarized in Tables 3, 4, and 5.
Discussion
Our results provide strong evidence supporting the rele-
vance of self-reported quality of life assessments for pa-
tients with cognitive disorders, particularly in patients
with severe cognitive dysfunction. It seems that the na-
ture of multiple sclerosis and schizophrenia did not
affect this type of assessment.
We examined these two diseases on the basis of the fol-
lowing points: i) the status of chronic illnesses with a high
occurrence of reported cognitive deficits, even during the
Figure 1 Suitability indices of construct validity according to the disease. LI no/low-impaired (0 or 1 impaired composites: executive,
memory, and attention functions); HI highly-impaired (2 or 3 impaired composites). MS multiple sclerosis, SCZ schizophrenia.
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cognition were indiscriminately affected [42,43]; iii) the
homogeneous and extensive assessment of cognition, in-
cluding tests assessing memory, attention, and executive
function; iv) the availability of a disease-specific self-
reported QoL questionnaire [30,32]; and v) the surprising
similarities related to changes in white matter structure or
abnormalities in myelin [24,25]. Moreover, some studies
have suggested that changes in the integrity of white mat-
ter can result in impaired cognitive function in MS [44]
and SCZ [45] patients.
These findings may support for the use of QoL assess-
ment for clinicians who are still perplexed when inter-
preting the meaning of QoL scores for an individual
with cognitive impairment. This present study suggests
that cognitively impaired patients, as defined by a global
cognitive dysfunction, can reliably and consistently re-
spond to a specific QoL self-reported questionnaire. This
assumption is underlined by the suitability indices found
in the highly-impaired groups, i.e., 2 or 3 altered func-
tions altered, in both MS and SCZ patients. These indi-
ces may be considered satisfactory compared to their
respective reference populations. In the highly-impaired
groups, factor analysis showed that the structure corre-
sponded with the initial structure of the QoL question-
naires: 8 of the 9 dimensions were clearly identified in
the MusiQoL and all the dimensions were identified in
the SQoL. Although the IIC values reported in the
highly-impaired population of MS individuals were simi-
lar to those identified in the reference population, the
proportion of dimensions with IIC that exceeded 0.2compared to the reference population was less satisfac-
tory in SCZ individuals. For MS and SCZ populations,
the proportion of dimensions with IDV values greater
than the IIC values and the proportion of dimensions
with IDV exceeding 0.2 compared to the reference po-
pulation were less satisfactory, which may be explained
by the very restricted definition of the decision rule.
Internal consistency coefficients calculated in the highly-
impaired groups were close to those of the initial refer-
ence populations. The floor and ceiling effects were
slightly different compared to those reported in the ini-
tial validation publication independent of disease type.
In addition, satisfactory INFIT statistics supported the
unidimensionality of each of the dimensions.
Regarding external validity, highly-impaired populations
showed satisfactory suitability indices. The links between
QoL scores and age, severity disease score (EDSS and
PANSS), and disease duration were closer to the initial ref-
erence populations independent of cognitive status and
disease. However, links between QoL scores and gender
and educational level were less satisfactory. In summary,
the suitability indices of the highly-impaired population
may be considered completely acceptable considering the
small sample size of the defined populations.
Several previous studies have employed similar ap-
proaches to define cognitive dysfunction using a single
composite, such as memory [7,15], attention [16], and ex-
ecutive functions [17,46]. It should be acknowledged that
a single test of cognitive functioning would never be en-
tirely appropriate to define an impaired cognitive popula-
tion. One composite cannot be a perfect reflection of
Table 2 Internal structural validity, reliability, unidimensionality according to the cognitive status
IIC1 Min-Max IDV2 Min-Max Floor % Ceiling % Alpha3 INFIT4
MS LI 50 HI 49 Ref 1992 LI 50 HI 49 Ref 1992 LI 50 HI 49 Ref 1992 LI 50 HI 49 Ref 1992 LI 50 HI 49 Ref 1992 LI 50 HI 49 Ref 1992
ADL 0.48-0.69 0.19-0.78 0.66-0.81 −0.32-0.40 −0.15-0.39 0,02-0,49 29.50 35.73 1,3 8.25 5.88 4,6 0.86 0.84 0,92 0.66-1.76 0.47-2.15 0,86-1,2
PWB 0.55-0.82 0.52-0.76 0,67-0,76 −0.16-0.44 −0.06-0.60 0,09-0,41 7.50 13.25 2,4 17.00 14.78 4,6 0.88 0.81 0,85 0.79-1.30 0.68-1.20 0,81-1,13
RFr 0.74-0.83 0.78-0.84 0,69-0,78 −0.23-0.42 −0.17-0.29 0,04-0,36 2.67 5.43 2,4 18.00 14.97 13 0.89 0.89 0,75 0.70-1.13 0.71-1.17 0,84-1,15
SPT 0.41-0.58 0.42-0.60 0,48-0,65 −0.09-0.49 −0.18-0.41 0,06-0,41 5.50 16.35 0,7 23.00 15.30 10,3 0.69 0.72 0,80 0.72-1.15 0.85-1.14 0,75-1,17
RFa 0.58-0.61 0.63-0.65 0,62-0,68 −0.35-0.47 −0.18-0.39 0,04-0,38 3.00 2.00 0,8 44.67 35.40 25,7 0.76 0.77 0,86 0.96-1.05 0.92-1.08 0,88-1,07
RHCS 0.44-0.65 0.47-0.60 0,42-0,56 −0.18-0.34 −0.19-0.22 0,05-0,32 0.67 2.73 0,3 28.67 19.7 24,5 0.71 0.72 0,68 0.97-1.29 0.79-1.21 0,83-1,18
SSL 0.43 0.77 0,75-0,75 −0.13-0.48 −0.9-0.31 0,15-0,43 17.00 26.5 7,6 23.00 10.2 18,7 0.64 0.85 0,85 0.93-1.04 0.95-1.03 0,98-1
COP 0.29 0.61 0,66-0,66 −0.14-0.46 −0.17-0.39 0,12-0,45 11.00 16.3 5,8 29.00 19.35 21,1 0.43 0.75 0,80 0.99 0.94-0.97 0,97-1
REJ 0.77 0.76 0,60-0,60 −0.14-0.37 −0.17-0.55 0,13-0,41 3.00 11.2 1,5 37.00 44.9 32,9 0.87 0.88 0,74 1.00-1.01 0.91-0.97 0,95-1,04
SCZ LI 40 HI 67 Ref 507 LI 40 HI 67 Ref 507 LI 40 HI 67 Ref 507 LI 40 HI 67 Ref 507 LI 40 HI 67 Ref 507 LI 40 HI 67 Ref 507
PsW 0,53 -0,63 0,4 -0,47 0.80-0.81 −0,15 -0,67 0,03 -0,44 0.13-0.46 0 3,3 13.9 27 18 35.1 0,76 0,63 0.73 0,89 -1,17 0,98 -1,08 0.91-1.05
SE 0,74 -0,74 0,68 -0,68 0.89-0.90 0,09 -0,77 0,09 -0,54 0.17-0.55 10,8 0 12.3 10,8 24,6 22.2 0,85 0,81 0.74 0,98 -1,01 0,97 -0,99 0.98-0.99
RFa 0,79 -0,79 0,77 -0,77 0.91-0.92 −0,28 -0,28 −0,07 -0,25 0.06-0.27 5,4 14,8 12.8 16,2 9,8 24.2 0,88 0,87 0.81 0,89 -0,9 0,97 -0,98 0.96-1.02
RFr 0,67 -0,67 0,68 -0,68 0.88-0.89 −0,03 -0,35 0,04 -0,53 0.16-0.34 8,1 16,4 21.3 2,7 13,1 12.8 0,8 0,81 0.73 0,92 -1,02 0,97 -1 0.98-1.00
Re 0,59 -0,76 0,47 -0,64 0.80-0.83 −0,01 -0,59 0,12 -0,51 0.03-0.49 0 0 10.5 16,2 21,3 24.2 0,82 0,73 0.74 0,74 -1,19 0,81 -1,2 0.96-1.03
PhW 0,44 -0,44 0,76 -0,76 0.83-0.84 −0,15 -0,67 0,12 -0,61 0.13-0.51 2,7 8,2 13.3 13,5 23 16.0 0,61 0,86 0.79 0,95 -0,99 0,95 -0,98 0.97-0.99
Au 0,72 -0,72 0,79 -0,79 0.92-0.93 −0,15 -0,68 −0,07 -0,57 0.07-0.45 2,7 4,9 10.2 16,2 13,1 18.7 0,84 0,88 0.84 0,94 -0,95 0,95 -0,99 0.98-0.99
SL 0,78 -0,78 0,49 -0,49 0.88-0.89 −0,01 -0,58 0,14 -0,63 0.16-0.48 18,9 19,7 28.8 10,8 3,3 12.7 0,88 0,65 0.72 0,93 -0,94 0,98 -1,04 0.98-1.01
1Item-Internal Consistency, 2Item Discriminant Validity, 3Cronbach’s alpha, 4Rasch statistics.
MS multiple sclerosis, SCZ schizophrenia.
MusiQoL: ADL activity of daily living, PWB psychological well-being, RFr relationships with friends, SPT symptoms, RFa relationships with family, RHCS relationships with health care system, SSL sentimental and sexual
life, COP coping, REJ rejection.
SQoL: PsW psychological well-being, SE self-esteem, RFa family relationships, RFr relationships with friends, RE: resilience, PhW physical well-being, AU autonomy, SL sentimental life.
LI no/low-impaired (0 or 1 of the 3 composites is impaired: executive, memory, and attention functions).
HI highly-impaired (2 or 3 composites are impaired).
Ref 1992 reference population of MusiQoL [30].
Ref 507 reference population of SQoL [32].
Bold values: unsatisfactory values.



















Table 3 Suitability indices of construct validity and external validity according to the cognitive status: a global
approach
MS SCZ
Construct validity LI 50 HI 49 LI 40 HI 67
% of identified factors 77.8 88.9 100 100
% of well-projected items 87.1 93.6 88.9 88.9
% of dimensions with IIC non exceeded 0.2 from ref 77.8 94.4 37.5 37.5
% of dimensions with IDV non exceeded 0.2 from ref 55.6 61.1 37.5 100
% of dimensions with IDV < IIC 66.7 77.8 62.5 62.5
% of dimensions with Cronbach’s alpha coefficients > =0.7 or > =ref 66.7 100 87.5 75.0
% of dimensions with INFIT ranged [0.7-1.3] 88.9 83.3 100 100
% of dimensions with MV < 10% from ref 100 100 100 100
% of dimensions with Floor < 10% from ref 88.9 44.4 75.0 75.0
% of dimensions with Ceiling < 10% from ref 66.7 77.8 50.0 62.5
External validity LI 50 HI 49 LI 40 HI 67
Age: % of dimensions with correlation coefficient < 0.40 100 100 100 100
Disease severity: % of dimensions meeting conditions* 100 88.9 75.0 100
Disease duration: % of dimensions with correlation coefficient < 0.40 100 100 100 100
Gender: % of dimensions with ES < 0.2 from ref 55.6 88.9 75.0 62.5
Educational level: % of dimensions with ES < 0.2 from ref 44.4 55.6 75.0 75.0
MS multiple sclerosis, SCZ schizophrenia.
*MusiQoL and EDSS, the two conditions were: i) correlation coefficient between ADL and EDSS > 0.4 and stronger than the other correlations for MusiQoL;
ii) all other correlation coefficients inferior to 0.40. SQoL and PANSS, the condition was correlation coefficient < 0.30 or not statistically significant. The score was
100% when all the dimensions met the condition.
LI no/low-impaired (0 or 1 impaired composites: executive. memory. and attention functions). HI highly-impaired (2 or 3 composites are impaired).
Figure 2 Suitability indices of external validity according to the disease. LI no/low-impaired (0 or 1 impaired composites: executive, memory,
and attention functions); HI highly-impaired (2 or 3 impaired composites). MS multiple sclerosis, SCZ schizophrenia.
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Table 4 Associations between QoL dimension scores and sociodemographic characteristics according to the cognitive
status
1. MS Gender Educational level 2. SCZ Gender Educational level
MusiQoL Women Men p Low High p SQoL Women Men p Low High p
ADL LI 32.9 ± 22.2 36.8 ± 20.9 0.29 22.4 ± 10.1 38.2 ± 22.6 0.03 PsW LI 73.8 ± 31.3 75.3 ± 24.1 0.75 77.5 ± 20.4 73.2 ± 28.3 0.87
HI 24.0 ± 16.3 29.9 ± 22.6 0.38 26.8 ± 16.6 25.7 ± 21.3 0.51 HI 56.3 ± 25.7 62.4 ± 27.1 0.30 56.5 ± 27.2 65.9 ± 24.9 0.08
PWB LI 46.5 ± 27.4 62.0 ± 20.2 0.03 33.7 ± 21.3 59.3 ± 23.7 0.00 SE LI 58.9 ± 33.6 62.9 ± 31.3 0.68 60.9 ± 33.5 63.0 ± 30.5 0.77
HI 43.3 ± 25.2 57.8 ± 21.7 0.08 54.7 ± 27.0 42.8 ± 21.2 0.09 HI 59.5 ± 28.5 64.0 ± 30.8 0.53 62.2 ± 31.1 62.5 ± 28.3 1
RFr LI 60.8 ± 25.5 64.5 ± 22.6 0.61 68.9 ± 26.1 60.7 ± 23.5 0.27 RFa LI 75.0 ± 12.5 67.6 ± 29.1 0.96 63.3 ± 30.1 72.8 ± 24.3 0.36
HI 66.1 ± 23.0 53.7 ± 25.8 0.06 58.0 ± 27.0 65.0 ± 22.0 0.36 HI 59.5 ± 37.2 64.6 ± 32.9 0.68 61.3 ± 36.6 65.0 ± 31.0 0.91
SPT LI 55.6 ± 23.0 68.2 ± 18.0 0.04 47.7 ± 25.0 65.2 ± 19.1 0.02 RFr LI 60.7 ± 19.7 47.7 ± 30.2 0.34 50.0 ± 30.9 50.0 ± 28.0 0.91
HI 48.3 ± 25.5 50.7 ± 21.7 0.69 46.1 ± 22.4 52.3 ± 21.3 0.53 HI 37.5 ± 30.8 59.4 ± 32.1 0.01 49.7 ± 36.0 53.0 ± 28.7 0.88
RFa LI 76.9 ± 21.1 75.0 ± 24.0 0.92 78.8 ± 27.0 75.2 ± 21.1 0.45 Re LI 72.6 ± 22.9 67.7 ± 35.3 0.58 71.4 ± 26.3 66.7 ± 23.8 0.51
HI 73.9 ± 23.2 70.4 ± 21.6 0.54 74.0 ± 23.7 71.1 ± 21.3 0.55 HI 57.3 ± 27.8 68.2 ± 25.5 0.10 62.1 ± 25.5 67.3 ± 38.7 0.32
RHCS LI 73.5 ± 16.8 73.9 ± 17.5 0.69 85.6 ± 14.9 70.3 ± 16.1 0.01 PhW LI 66.1 ± 25.7 64.8 ± 25.1 0.90 73.4 ± 21.3 59.2 ± 25.9 0.10
HI 64.4 ± 16.4 65.7 ± 24.9 0.72 69.1 ± 20.3 60.8 ± 18.6 0.11 HI 45.8 ± 30.7 61.9 ± 32.8 0.05 52.5 ± 34.5 61.5 ± 29.8 0.30
SSL LI 59.2 ± 30.0 50.0 ± 30.9 0.35 50.0 ± 33.9 56.1 ± 29.8 0.68 Au LI 67.9 ± 34.5 68.4 ± 21.1 0.68 68.0 ± 22.8 68.5 ± 24.4 0.90
HI 43.3 ± 31.6 33.3 ± 30.5 0.28 44.6 ± 36.3 35.2 ± 24.9 0.38 HI 59.0 ± 35.5 68.2 ± 24.7 0.41 64.6 ± 29.2 64.9 ± 30.0 0.94
COP LI 53.7 ± 30.0 66.3 ± 21.1 0.07 46.6 ± 25.1 63.1 ± 26.4 0.09 SL LI 58.3 ± 30.3 37.9 ± 32.1 0.15 43.4 ± 30.3 39.2 ± 34.4 0.62
HI 47.1 ± 30.0 54.2 ± 32.9 0.45 49.0 ± 30.4 50.5 ± 32.2 0.89 HI 42.0 ± 31.0 45.5 ± 34.1 0.71 44.5 ± 33.4 43.8 ± 32.5 0.89
REJ LI 59.3 ± 31.1 75.0 ± 25.6 0.06 58.0 ± 31.8 68.9 ± 28.8 0.29 Index LI 66.5 ± 24.9 61.4 ± 16.0 0.36 63.5 ± 16.2 61.4 ± 18.5 0.80
HI 63.8 ± 36.0 77.1 ± 30.4 0.18 68.8 ± 36.7 68.8 ± 32.6 0.67 HI 53.0 ± 19.6 61.4 ± 19.8 0.11 57.5 ± 18.8 59.3 ± 22.3 0.87
Index LI 57.3 ± 11.4 63.3 ± 13.3 0.13 53.3 ± 15.7 62.2 ± 11.0 0.12
HI 52.7 ± 11.8 55.6 ± 15.5 0.36 54.0 ± 12.7 53.3 ± 13.7 0.86
MS multiple sclerosis. SCZ schizophrenia.
MusiQoL: ADL activity of daily living. PWB psychological well-being. RFr relationships with friends. SPT symptoms. RFa relationships with family. RHCS relationships
with health care system. SSL sentimental and sexual life. COP coping. REJ rejection.
SQoL: PsW psychological well-being. SE self-esteem. RFa family relationships. RFr relationships with friends. RE: resilience. PhW physical well-being. AU autonomy.
SL sentimental life.
LI no/low-impaired (0 or 1 impaired composites: executive. memory. and attention functions). HI highly-impaired (2 or 3 composites are impaired).
Bold values: p < 0.05.
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http://www.biomedcentral.com/1471-2377/14/78global cognitive function because patients suffer from
several neuropsychological deficits. It would be unusual
to observe one deficit in isolation [20,47-49], and QoL
measurement may be altered depending on the type of
cognitive impairment [50]. Thus, it is necessary to re-
port additional information according to other defini-
tions of cognitive dysfunction using a combination of
different composites. To the best of our knowledge, this
is the first study that uses the definition of cognitive
dysfunction, which integrates a combination of different
composites (i.e., memory, attention, and concentration).
Several limitations and strengths of this study should
be mentioned:
1. The representativeness of the samples should be
discussed. Compared to international and European
cohorts, the MS patients in this study exhibited a
more severe disability profile [30,51], and the SCZ
patients had a longer illness duration [52]. Thus, anassessment of the reproducibility of our results is
needed, using a larger and more diverse group of
patients. However, the proportion of cognitively
impaired subjects was consistent with the literature
for MS [13,20,53] and SCZ [54,55] domains.
2. One important aspect of this study concerns our
definition of cognitive dysfunction because there is
little consensus according to Achiron and Barak [56].
We defined cognitive impairment using tests in which
the French norms have been previously published
[35-37]. This eliminated the need for a control group
and enabled a consensus in defining patients as non-
impaired or impaired for each test. However, our
definition may be questionable because of the absence
of a consensus on a ‘global definition’ of a patient with
global cognitive dysfunction on the basis of a
combination of these tests. However, we are convinced
that our findings, independent of the definition of
cognitive dysfunction, can help researchers to better
Table 5 Correlations between QoL dimension scores and age and clinical features according to the cognitive status
1. MS 2. SCZ
MusiQoL Age EDSS MS duration SQoL Age PANSS SCZ duration
ADL LI −0.08 −0.46** −0.01 PsW LI 0.21 −0.34* 0.15
HI −0.05 −0.33* −0.05 HI 0.08 −0.25* 0.16
PWB LI 0.17 0.07 −0.07 SE LI 0.05 −0.26 −0.08
HI 0.11 0.08 −0.11 HI 0.04 0.00 0.10
RFr LI 0.05 0.22 0.06 RFa LI −0.22 −0.12 −0.29
HI 0.10 0.22 0.25 HI −0.08 −0.19 0.07
SPT LI 0.02 0.07 0.08 RFr LI −0.23 −0.18 −0.02
HI 0.14 0.16 0.04 HI −0.14 −0.08 0.08
RFa LI −0.06 −0.04 −0.27 Re LI 0.13 −0.49** 0.10
HI −0.06 0.15 0.06 HI −0.23 −0.14 −0.12
RHCS LI 0.00 −0.09 −0.06 PhW LI 0.05 −0.23 −0.03
HI 0.16 −0.03 0.04 HI −0.04 0.02 −0.05
SSL LI 0.09 −0.02 0.10 Au LI 0.32 −0.18 0.28
HI −0.19 −0.08 −0.17 HI −0.02 0.00 −0.05
COP LI 0.29* 0.07 0.11 SL LI 0.13 −0.20 0.22
HI 0.03 −0.03 −0.08 HI 0.17 −0.24 0.22
REJ LI 0.28 0.13 0.09 Index LI 0.01 −0.37* 0.04
HI 0.00 0.20 0.06 HI −0.08 −0.15 0.07
Index LI 0.30* 0.08 0.16
HI −0.01 0.09 −0.02
MS multiple sclerosis. SCZ schizophrenia.
EDSS Expanded Disability Status Scale, PANSS Positive and Negative Syndrome Scale.
MusiQoL: ADL activity of daily living. PWB psychological well-being. RFr relationships with friends. SPT symptoms. RFa relationships with family. RHCS relationships
with health care system. SSL sentimental and sexual life. COP coping. REJ rejection.
SQoL: PsW psychological well-being. SE self-esteem. RFa family relationships. RFr relationships with friends. RE: resilience. PhW physical well-being. AU autonomy.
SL sentimental life.
LI no/low-impaired (0 or 1 impaired composites: executive. memory. and attention functions). HI highly-impaired (2 or 3 composites are impaired).
Spearman rank correlation coefficients were presented. *p-value <0.05. **p-value <0.01.
Bold values: p < 0.05.
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http://www.biomedcentral.com/1471-2377/14/78understand the relevance of self-reported quality of life
assessments for patients with cognitive disorders.
3. The suitability indices used to define the satisfactory
properties relied on arbitrary decision rules, each of
which will be discussed. Nevertheless, this approach
enabled the determination of the suitability or
unsuitability of different structures using the same
decision tree independent of the questionnaire and
disease. Thus, future studies may be performed to
test different decision trees and to discuss the
implications of the subsequent results.
4. Factors previously associated to cognitive
performance, such as depression and fatigue [57,58],
and medications [59] were not considered. However,
the aim of this study was to provide evidence
supporting the conclusion that cognitively impaired
patients reliably answer a self-reported QoL
questionnaire regardless of the presence or absence
of other factors that could have influenced their
performance.Conclusion
These findings confirmed preliminary results, which sug-
gest that cognitive decline, as defined using a global cog-
nitive dysfunction, did not compromise the reliability or
validity of self-reported health measures. This study
should support the clinical relevance of QoL assessment,
thereby enhancing the use of QoL measures in clinical
practice for cognitively impaired patients.Competing interest
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